InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 2 February 2024

LASER: This phase I trial will evaluate whether stereotactic ablative radiotherapy (SABR) is a safe and effective treatment option for patients with non-small cell lung cancer (NSCLC) whose cancer is large and/or has spread to the nearby lymph nodesTreatment of Locally Advanced non-small cell lung carcinoma with Stereotactic ablativE Radiotherapy

Clinical summary

Summary

Stereotactic ablative radiotherapy (SABR) is a specialised form of radiotherapy whereby large doses of radiation are given in fewer treatments. Patients participating in this trial will attend between 6-12 SABR sessions across 2-3 weeks, and will then be followed up regularly post radiotherapy, in order to evaluate treatment safety, quality of life, tumour response and survival.

Conditions

This trial is treating patients with non-small cell lung cancer

Cancer

Lung Cancers Lung cancer

Age

People18+

Phase

I

Trial Acronym

LASER

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

Alfred Health

Scientific Title

Treatment of Locally Advanced non-small cell lung carcinoma with Stereotactic ablativE Radiotherapy

Eligibility

Inclusion

- Diagnosis of stage III or IV non-small cell lung carcinoma. Based on clinical or histologic grounds.
- Ineligible for standard of care concurrent chemoradiotherapy as determined by a multidisciplinary group.
- Estimated life expectancy >6 months. Scoring using a Victorian Lung Cancer Prognostic Index is suggested for guidance.
- Recommended a course of radiotherapy to the lung and mediastinal disease.
- Over 18 years of age and available for follow up.

Exclusion

- Previous radiotherapy to the chest.
- History of another primary cancer within the last 2 years, with the exception of non-melanomatous skin cancer and carcinoma in situ of the cervix.
- Significant medical conditions which in the opinion of the investigator would compromise the planned delivery of the radiotherapy or which may be potentially exacerbated by the treatment.
- Pregnant or breast feeding.

Exclusion

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Cancer Connect

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Get support

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

More info for carers

CloseReport inaccuracy

Thank you for helping us to increase accuracy of the trial. Our team will validate the information and update the information as soon as possible.

HelpThis verification step helps prevent fraudulent transactions from automated software.
Submitting ... Please wait

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.